| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Letter
- Language: English
- [Br J Haematol] 2023 Aug; Vol. 202 (3), pp. 699-703. <i>Date of Electronic Publication: </i>2023 Jun 02.
- MeSH Terms: Thrombocythemia, Essential* ; Venous Thrombosis* ; Thrombosis* ; Humans ; ABO Blood-Group System ; Blood Grouping and Crossmatching ; Risk Factors
- References: Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117:5857-9. ; Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:1599-613. ; Barbui T, Vannucchi AM, Buxhofer-Ausch V, de Stefano V, Betti S, Rambaldi A, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369. ; Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, Hanson C, et al. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol. 2016;91:390-4. ; Barbui T. Refining prognostication of thrombosis in ET. Am J Hematol. 2016;91:361-3. ; Tefferi A, Pardanani A. Essential thrombocythemia. N Engl J Med. 2019;381:2135-44. ; Gangat N, Szuber N, Jadoon Y, Farrukh F, Begna K, Elliott MA, et al. 1.5 Million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events. Blood Adv. 2022;6:3835-9. ; Vasan SK, Rostgaard K, Majeed A, Ullum H, Titlestad KE, Pedersen OBV, et al. ABO blood group and risk of thromboembolic and arterial disease. Circulation. 2016;133:1449-57. ; Englisch C, Moik F, Nopp S, Raderer M, Pabinger I, Ay C. ABO blood group type and risk of venous thromboembolism in patients with cancer. Blood Adv. 2022;6:6274-81. ; Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood. 2022;140:1200-28. ; Getawa S, Bayleyegn B, Aynalem M, Worku YB, Adane T. Relationships of ABO and Rhesus blood groups with type 2 diabetes mellitus: a systematic review and meta-analysis. J Int Med Res. 2022;50:3000605221129547. ; Heenkenda MK, Malmstrom A, Lysiak M, Mudaisi M, Bratthäll C, Milos P, et al. Assessment of genetic and non-genetic risk factors for venous thromboembolism in glioblastoma - the predictive significance of B blood group. Thromb Res. 2019;183:136-42. ; Baudouy D, Moceri P, Chiche O, Bouvier P, Schouver ED, Cerboni P, et al. B blood group: a strong risk factor for venous thromboembolism recurrence. Thromb Res. 2015;136:107-11. ; Ward SE, O'Sullivan JM, O'Donnell JS. The relationship between ABO blood group, von Willebrand factor, and primary hemostasis. Blood. 2020;136:2864-74. ; Carobbio A, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019;3:1729-37. ; Farrukh F, Guglielmelli P, Loscocco GG, Pardanani A, Hanson CA, de Stefano V, et al. Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. Am J Hematol. 2022;97:E35-7. ; Gangat N, Singh A, Szuber N, Begna K, Elliott M, Wolanskyj-Spinner A, et al. Site-specific venous thrombosis in essential thrombocythemia: impact on subsequent vascular events and survival. J Thromb Haemost. 2022;20:2439-43. ; de Stefano V, Finazzi G, Barbui T. Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms. Blood Cancer J. 2018;8:65.
- Substance Nomenclature: 0 (ABO Blood-Group System)
- Entry Date(s): Date Created: 20230602 Date Completed: 20230726 Latest Revision: 20230726
- Update Code: 20231215
|
